A comparison of Symbicort single inhaler therapy (Symbicort Turbohaler [Turbuhaler] 160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults - a 26-week, randomised, open-label, parallel-group, multi-centre study (SALTO).

Trial Profile

A comparison of Symbicort single inhaler therapy (Symbicort Turbohaler [Turbuhaler] 160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults - a 26-week, randomised, open-label, parallel-group, multi-centre study (SALTO).

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2013

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms SALTO
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Oct 2009 Results published in the International Journal of Clinical Practice.
    • 29 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top